Financhill
Sell
25

TKNO Quote, Financials, Valuation and Earnings

Last price:
$5.60
Seasonality move :
-37.07%
Day range:
$5.41 - $5.65
52-week range:
$1.16 - $10.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.96x
P/B ratio:
3.64x
Volume:
142.3K
Avg. volume:
419.1K
1-year change:
97.19%
Market cap:
$300.3M
Revenue:
$37.7M
EPS (TTM):
-$0.59

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
TKNO
Alpha Teknova
$8.7M -- 0.73% -- $10.67
GERN
Geron
$45.3M -$0.05 16309.12% -60.37% $4.50
NBY
NovaBay Pharmaceuticals
$2.5M -$0.24 14.03% -95.43% $0.85
PTN
Palatin Technologies
-- -$0.42 -100% -67.93% $7.00
TOVX
Theriva Biologics
-- -$5.50 -- -8.25% $6.00
ZVRA
Zevra Therapeutics
$8.9M -$0.40 395.13% -53.57% $21.63
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
TKNO
Alpha Teknova
$5.62 $10.67 $300.3M -- $0.00 0% 6.96x
GERN
Geron
$1.73 $4.50 $1.1B -- $0.00 0% 14.51x
NBY
NovaBay Pharmaceuticals
$0.63 $0.85 $3.1M -- $0.00 0% 0.07x
PTN
Palatin Technologies
$0.80 $7.00 $20.7M -- $0.00 0% --
TOVX
Theriva Biologics
$1.19 $6.00 $3.3M -- $0.00 0% 1.59x
ZVRA
Zevra Therapeutics
$8.31 $21.63 $449.7M -- $0.00 0% 16.27x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
TKNO
Alpha Teknova
14.07% 0.863 3.02% 3.10x
GERN
Geron
29.71% 1.676 5.52% 5.04x
NBY
NovaBay Pharmaceuticals
4.54% 0.646 1.51% 0.75x
PTN
Palatin Technologies
-- -1.737 -- 0.99x
TOVX
Theriva Biologics
-- -2.868 -- --
ZVRA
Zevra Therapeutics
60% 1.594 13.29% 2.35x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
TKNO
Alpha Teknova
$2.1M -$5.6M -27.37% -31.69% -60.75% -$1.5M
GERN
Geron
$46.8M -$20.1M -45.4% -59.29% -35.02% -$43.8M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
PTN
Palatin Technologies
-- -$5.1M -- -- -2356.3% -$4.8M
TOVX
Theriva Biologics
-- -$4.6M -- -- -- -$4.7M
ZVRA
Zevra Therapeutics
$10.7M -$15.4M -102.42% -208.85% -150.91% -$16.3M

Alpha Teknova vs. Competitors

  • Which has Higher Returns TKNO or GERN?

    Geron has a net margin of -61.73% compared to Alpha Teknova's net margin of -53.33%. Alpha Teknova's return on equity of -31.69% beat Geron's return on equity of -59.29%.

    Company Gross Margin Earnings Per Share Invested Capital
    TKNO
    Alpha Teknova
    22.97% -$0.11 $95.9M
    GERN
    Geron
    98.35% -$0.04 $398.8M
  • What do Analysts Say About TKNO or GERN?

    Alpha Teknova has a consensus price target of $10.67, signalling upside risk potential of 95.73%. On the other hand Geron has an analysts' consensus of $4.50 which suggests that it could grow by 160.12%. Given that Geron has higher upside potential than Alpha Teknova, analysts believe Geron is more attractive than Alpha Teknova.

    Company Buy Ratings Hold Ratings Sell Ratings
    TKNO
    Alpha Teknova
    4 2 0
    GERN
    Geron
    4 2 0
  • Is TKNO or GERN More Risky?

    Alpha Teknova has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Geron has a beta of 0.535, suggesting its less volatile than the S&P 500 by 46.549%.

  • Which is a Better Dividend Stock TKNO or GERN?

    Alpha Teknova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova pays -- of its earnings as a dividend. Geron pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TKNO or GERN?

    Alpha Teknova quarterly revenues are $9.3M, which are smaller than Geron quarterly revenues of $47.5M. Alpha Teknova's net income of -$5.7M is higher than Geron's net income of -$25.4M. Notably, Alpha Teknova's price-to-earnings ratio is -- while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova is 6.96x versus 14.51x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TKNO
    Alpha Teknova
    6.96x -- $9.3M -$5.7M
    GERN
    Geron
    14.51x -- $47.5M -$25.4M
  • Which has Higher Returns TKNO or NBY?

    NovaBay Pharmaceuticals has a net margin of -61.73% compared to Alpha Teknova's net margin of -49.65%. Alpha Teknova's return on equity of -31.69% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    TKNO
    Alpha Teknova
    22.97% -$0.11 $95.9M
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About TKNO or NBY?

    Alpha Teknova has a consensus price target of $10.67, signalling upside risk potential of 95.73%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 34.92%. Given that Alpha Teknova has higher upside potential than NovaBay Pharmaceuticals, analysts believe Alpha Teknova is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    TKNO
    Alpha Teknova
    4 2 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is TKNO or NBY More Risky?

    Alpha Teknova has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

  • Which is a Better Dividend Stock TKNO or NBY?

    Alpha Teknova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TKNO or NBY?

    Alpha Teknova quarterly revenues are $9.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Alpha Teknova's net income of -$5.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Alpha Teknova's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova is 6.96x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TKNO
    Alpha Teknova
    6.96x -- $9.3M -$5.7M
    NBY
    NovaBay Pharmaceuticals
    0.07x -- $2.4M -$1.2M
  • Which has Higher Returns TKNO or PTN?

    Palatin Technologies has a net margin of -61.73% compared to Alpha Teknova's net margin of -2357.27%. Alpha Teknova's return on equity of -31.69% beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    TKNO
    Alpha Teknova
    22.97% -$0.11 $95.9M
    PTN
    Palatin Technologies
    -- -$0.12 -$111.5K
  • What do Analysts Say About TKNO or PTN?

    Alpha Teknova has a consensus price target of $10.67, signalling upside risk potential of 95.73%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 780.5%. Given that Palatin Technologies has higher upside potential than Alpha Teknova, analysts believe Palatin Technologies is more attractive than Alpha Teknova.

    Company Buy Ratings Hold Ratings Sell Ratings
    TKNO
    Alpha Teknova
    4 2 0
    PTN
    Palatin Technologies
    0 0 0
  • Is TKNO or PTN More Risky?

    Alpha Teknova has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

  • Which is a Better Dividend Stock TKNO or PTN?

    Alpha Teknova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TKNO or PTN?

    Alpha Teknova quarterly revenues are $9.3M, which are larger than Palatin Technologies quarterly revenues of $350K. Alpha Teknova's net income of -$5.7M is lower than Palatin Technologies's net income of -$2.4M. Notably, Alpha Teknova's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova is 6.96x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TKNO
    Alpha Teknova
    6.96x -- $9.3M -$5.7M
    PTN
    Palatin Technologies
    -- -- $350K -$2.4M
  • Which has Higher Returns TKNO or TOVX?

    Theriva Biologics has a net margin of -61.73% compared to Alpha Teknova's net margin of --. Alpha Teknova's return on equity of -31.69% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    TKNO
    Alpha Teknova
    22.97% -$0.11 $95.9M
    TOVX
    Theriva Biologics
    -- -$1.60 --
  • What do Analysts Say About TKNO or TOVX?

    Alpha Teknova has a consensus price target of $10.67, signalling upside risk potential of 95.73%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 404.2%. Given that Theriva Biologics has higher upside potential than Alpha Teknova, analysts believe Theriva Biologics is more attractive than Alpha Teknova.

    Company Buy Ratings Hold Ratings Sell Ratings
    TKNO
    Alpha Teknova
    4 2 0
    TOVX
    Theriva Biologics
    0 0 0
  • Is TKNO or TOVX More Risky?

    Alpha Teknova has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.159, suggesting its more volatile than the S&P 500 by 15.945%.

  • Which is a Better Dividend Stock TKNO or TOVX?

    Alpha Teknova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TKNO or TOVX?

    Alpha Teknova quarterly revenues are $9.3M, which are larger than Theriva Biologics quarterly revenues of --. Alpha Teknova's net income of -$5.7M is lower than Theriva Biologics's net income of -$4.4M. Notably, Alpha Teknova's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova is 6.96x versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TKNO
    Alpha Teknova
    6.96x -- $9.3M -$5.7M
    TOVX
    Theriva Biologics
    1.59x -- -- -$4.4M
  • Which has Higher Returns TKNO or ZVRA?

    Zevra Therapeutics has a net margin of -61.73% compared to Alpha Teknova's net margin of -296.76%. Alpha Teknova's return on equity of -31.69% beat Zevra Therapeutics's return on equity of -208.85%.

    Company Gross Margin Earnings Per Share Invested Capital
    TKNO
    Alpha Teknova
    22.97% -$0.11 $95.9M
    ZVRA
    Zevra Therapeutics
    88.66% -$0.69 $99.2M
  • What do Analysts Say About TKNO or ZVRA?

    Alpha Teknova has a consensus price target of $10.67, signalling upside risk potential of 95.73%. On the other hand Zevra Therapeutics has an analysts' consensus of $21.63 which suggests that it could grow by 160.23%. Given that Zevra Therapeutics has higher upside potential than Alpha Teknova, analysts believe Zevra Therapeutics is more attractive than Alpha Teknova.

    Company Buy Ratings Hold Ratings Sell Ratings
    TKNO
    Alpha Teknova
    4 2 0
    ZVRA
    Zevra Therapeutics
    4 0 0
  • Is TKNO or ZVRA More Risky?

    Alpha Teknova has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zevra Therapeutics has a beta of 1.977, suggesting its more volatile than the S&P 500 by 97.719%.

  • Which is a Better Dividend Stock TKNO or ZVRA?

    Alpha Teknova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova pays -- of its earnings as a dividend. Zevra Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TKNO or ZVRA?

    Alpha Teknova quarterly revenues are $9.3M, which are smaller than Zevra Therapeutics quarterly revenues of $12M. Alpha Teknova's net income of -$5.7M is higher than Zevra Therapeutics's net income of -$35.7M. Notably, Alpha Teknova's price-to-earnings ratio is -- while Zevra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova is 6.96x versus 16.27x for Zevra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TKNO
    Alpha Teknova
    6.96x -- $9.3M -$5.7M
    ZVRA
    Zevra Therapeutics
    16.27x -- $12M -$35.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Pepsi Vs Coke Stock: Which Is Best?
Pepsi Vs Coke Stock: Which Is Best?

Coca-Cola (NYSE:KO) and PepsiCo (NYSE:PEP) are two of the largest…

Is CyberArk The Next Big Cybersecurity Stock?
Is CyberArk The Next Big Cybersecurity Stock?

CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Sell
48
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Alerts

Buy
52
RGC alert for Mar 19

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Sell
46
CVNA alert for Mar 19

Carvana [CVNA] is down 10.69% over the past day.

Buy
93
ESLT alert for Mar 19

Elbit Systems [ESLT] is up 10.52% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock